Analytical methods for synthetic peptides: HPLC and mass spectrometry

Anyone working with synthetic peptides eventually meets two numbers: a purity percentage from high-performance liquid chromatography (HPLC), and a molecular mass from mass spectrometry. They are often quoted together, and they are easily confused. They answer different questions. HPLC purity describes how much of what the instrument detected sits in the main peak. Mass spectrometry helps establish whether that main component is the molecule it is supposed to be. This article explains how each method works, what it measures, and where its limits lie.

Why synthetic peptides need analysis

Most peptides are made by solid-phase peptide synthesis, in which amino acids are added one at a time to a growing chain. Each step is efficient but not perfect, and the process leaves characteristic by-products. A detailed review of impurities in peptide medicines groups them into families^[1]:

• Synthesis-related impurities, including sequences with a missing amino acid (deletions) or an extra one (insertions), amino acids that have flipped to the wrong mirror-image form, fragments still carrying protecting groups, oxidised side chains and dimers.
• Residual counter-ions, such as trifluoroacetate, carried over from synthesis and purification.
• Degradation products, formed through chemical pathways such as β-elimination and the formation of diketopiperazine, pyroglutamate and succinimide.
• Contamination by unrelated peptides, which the review's authors linked to a lack of appropriate good manufacturing practice.

The same review warns that such impurities can influence early functional studies and lead to erroneous conclusions^[1]. Many of these impurities are very close in structure to the intended peptide, which is why analysis needs methods able to tell near-identical molecules apart.

How reversed-phase HPLC works

The workhorse method for peptide purity is reversed-phase HPLC. The sample is injected into a column packed with a hydrophobic stationary phase. A liquid mobile phase is pumped through, usually starting with a high proportion of water and gradually increasing the proportion of an organic solvent such as acetonitrile. Peptides stick to the stationary phase according to their hydrophobicity and are released as the solvent strength rises, so different molecules leave the column at different times^[2]. As they emerge, a detector, most often measuring ultraviolet absorbance by the peptide bond, records a signal that is plotted against time as a chromatogram.

Retention time

The time at which a compound emerges is its retention time. Under a fixed method, meaning the same column, mobile phases, gradient, flow rate and temperature, a given peptide elutes at a reproducible time. Retention time is therefore useful for comparing a sample with a reference standard run under the same conditions.

It is not proof of identity. Retention time depends on the whole method, so a value is only meaningful alongside the method that produced it. More importantly, two different molecules can emerge at the same time, particularly when they are closely related.

Peak integration and chromatographic purity

Software measures the area under each peak. Chromatographic purity is usually reported as the area of the main peak divided by the total area of all integrated peaks, expressed as a percentage. A result of 98% means that, of everything the detector saw and the software integrated, 98% of the signal fell in the main peak.

That definition carries several assumptions. It assumes impurities respond to the detector in roughly the same way as the main compound, and that every relevant impurity was separated from the main peak and integrated. The number also depends on integration settings, such as where the baseline is drawn and which small peaks are counted.

The limits of an HPLC percentage

• It measures relative signal, not content. Water, salts and counter-ions such as trifluoroacetate contribute to the weight of a sample^[1], but not to the chromatographic purity figure. A peptide can show high chromatographic purity while a substantial part of the powder's mass is something else. Determining how much peptide is actually present is a separate measurement. Consensus recommendations for peptides used in quantitative mass spectrometry assays highlight carefully characterised reference materials and amino acid analysis for that purpose^[3].
• Co-eluting impurities are invisible. An impurity that emerges at the same time as the main peak is counted as part of it.
• The method defines the answer. A different column or gradient can separate impurities that a first method merged. A purity figure without method details cannot be compared with another.
• It says nothing about identity. A single sharp peak shows that the sample is chromatographically uniform. It does not show that the uniform material is the intended peptide.

What mass spectrometry measures

Mass spectrometry converts molecules into charged ions and measures their mass-to-charge ratio. For peptides, electrospray ionisation is widely used, often coupled directly to liquid chromatography (LC-MS), so that each component leaving the column can be examined as it elutes. In tandem mass spectrometry (MS/MS), selected ions are broken into fragments whose masses reveal information about the amino acid sequence. These capabilities underpin modern proteomics, where mass spectrometry is used to identify and increasingly to quantify thousands of proteins in complex samples^[4].

For a synthetic peptide, the most basic mass spectrometry question is whether the observed molecular mass matches the mass calculated from the intended sequence. Fragmentation data can then support the sequence itself.

The limits of mass alone

Mass spectrometry is powerful, but it has its own blind spots:

• Molecules with the same composition in a different order, or with an amino acid in the wrong mirror-image form, can have identical masses.
• The size of a mass spectrometry signal depends on how easily each molecule ionises, so signal intensity is not a simple measure of purity or quantity. Accurate quantification usually relies on well-characterised standards, often isotope-labelled^[3].
• A correct mass confirms that the intended molecule is present. It does not show how much of the sample it accounts for.

Purity and identity are different questions

A cautionary case from the research literature

The importance of this distinction was illustrated in a 2008 study of obestatin, a peptide whose original receptor-binding findings its own discoverers had reported being unable to reproduce. The investigators obtained obestatin from five different manufacturers, the products used by different research groups, and analysed them with liquid chromatography using optical detection and with LC-MS. One product turned out to be a different peptide altogether. Of the others, two-thirds were judged unsuitable for experiments, with purity below 95% or individual impurities above 1%. The authors suggested that these quality problems could help explain the conflicting results in the literature, and recommended appropriate quality control testing before any peptide is used in biomedical research^[5].

Why methods are used together

Because each technique answers a different question, quality specifications for peptide medicines treat identification, purity and assay (content) as separate elements. A review comparing pharmacopoeial peptide monographs found that these specifications were not fully harmonised, with notable differences between the European Pharmacopoeia and the United States Pharmacopeia, and even inconsistencies within a single pharmacopoeia^[6].

Control laboratories also combine methods. A European official medicines control laboratory developed an LC-MS/MS screening method to identify peptides in suspected counterfeit and illegal injectable products, using multiple identification points. It paired this with a separate liquid chromatography method with diode array detection to quantify them^[7]. Researchers from the same institution later analysed two unknown seized preparations, which turned out to contain the research peptides Selank and Semax, and developed an LC-MS/MS method for ten such peptides sold online^[8]. In each case, establishing what a product contains required mass spectrometric identification, not a purity percentage alone.

Reading an analytical report critically

When interpreting any analytical report for a synthetic peptide, a few questions help separate informative data from reassuring numbers:

1. Is the method described? Column, mobile phases, gradient and detection wavelength are needed to interpret a purity figure.
2. Is the chromatogram shown? The trace and its integrated peaks reveal more than a single percentage.
3. Was identity tested? Look for an observed molecular mass compared with the theoretical mass, ideally with fragmentation data.
4. Is content addressed? Chromatographic purity is not the same as the proportion of the sample's weight that is peptide.
5. Are identity and purity from the same sample and batch? Results from different material cannot be combined.

Summary

HPLC and mass spectrometry are complementary. Reversed-phase HPLC separates a peptide from its closely related impurities and expresses the result as chromatographic purity, a relative measure that depends on the method. Mass spectrometry measures molecular mass and, with fragmentation, sequence information, which makes it the principal tool for confirming identity. Neither answers the other's question, and neither on its own measures how much peptide a sample contains. The obestatin case shows the consequences of overlooking this: without identity testing, a research group could study the wrong molecule without knowing it.